title: Efficacy without barriers to insulin therapy: lessons from the BEGIN trial programme.
abstract: Insulin degludec has been extensively studied in the BEGIN programme in a range of patients with type 1 or type 2 diabetes. The programme includes insulin-naive type 2 diabetes, insulin-treated type 2 and type 1 diabetes which are investigated as basal-bolus therapy, basal plus oral therapy, and basal vs. oral therapy and also the flexible dosing options. In all insulin degludec phase 3 trials, the efficacy of once daily insulin degludec was established, as insulin degludec being non-inferior to comparators in reducing HbA(1c). Also the flexible dosing option is an attractive feature of this insulin that mightimprove adherence to therapy and conceivably improve outcomes.
authors.forename: Ambrish
authors.initials: A
authors.lastname: Mithal
authors.forename: Ajay
authors.initials: A
authors.lastname: Kumar
authors.forename: Sunil M
authors.initials: SM
authors.lastname: Jain
authors.forename: Harish
authors.initials: H
authors.lastname: Kumar
mesh_terms: D001786:Blood Glucose / Q000032:analysis; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006442:Glycated Hemoglobin; D006801:Humans; D049528:Insulin, Long-Acting / Q000008:administration & dosage / Q000627:therapeutic use*; D010349:Patient Compliance
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D049528:Insulin, Long-Acting; C571886:insulin degludec